{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-075439","form_type":"8-K","ticker":"LQDA","cik":"0001819576","company_name":"Liquidia Corp","filed_at":"2023-06-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.840414+00:00","generated_at":"2026-06-13T15:40:14.572152+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Liquidia exclusively licenses L606 (inhaled treprostinil) for N. America; $10M upfront, up to $215M milestones","bullets":["Exclusive license from Pharmosa for development/commercialization of L606 in North America for PAH and PH-ILD.","Upfront $10M funded via HCR revenue-interest financing amendment; total HCR draws now $42.5M of $100M facility.","Milestone payments up to $215M for PAH/PH-ILD indications, plus $10M per additional indication/product; low double-digit royalties.","L606 is a twice-daily sustained-release inhaled treprostinil; ongoing Phase 3 open-label study; NDA planned via 505(b)(2) pathway.","Patent-litigation dependent $35M tranche remains unchanged; webcast held June 28, 2023 at 8:30 AM ET."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-075439","json":"https://secwatch.observer/filing/0001104659-23-075439.json","markdown":"https://secwatch.observer/filing/0001104659-23-075439.md","text":"https://secwatch.observer/filing/0001104659-23-075439.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819576/000110465923075439/0001104659-23-075439-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819576/000110465923075439/tm2319810d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T15:40:14.572152+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8632aa8956628136cc942bdf1cac0383851b677b","claim":"Liquidia Corp amended Second Amendment to Revenue Interest Financing Agreement with HealthCare Royalty Partners IV, L.P. and HealthCare Royalty Management, LLC valued at Amendment moves $2.5 million from fourth tranche to second tranche, resulting in $10 million total s (effective 2023-06-28).","evidence_excerpt":"On June 28, 2023, Liquidia Technologies and HCR entered into a Second Amendment to the Financing Agreement (the “Second Amendment”), pursuant to which, HCR will move $2.5 million from the fourth tranche to the second tranche under the Financing Agreement. As a result, HCR will fund a total of $10 million (as the second tranche under the Financing Agreement), which will be used for the upfront payment owed to Pharmosa in connection with the transactions contemplated by the License Agreement.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1819576/000110465923075439/0001104659-23-075439-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"credit facility"},{"label":"Counterparty","value":"HealthCare Royalty Partners IV, L.P. and HealthCare Royalty Management, LLC"},{"label":"Value","value":"Amendment moves $2.5 million from fourth tranche to second tranche, resulting in $10 million total s"},{"label":"Effective","value":"2023-06-28"}],"fact_type":"material_agreement"},{"claim_id":"fe5914589ca681db3f2a783742b8796a79870d16","claim":"Liquidia Corp entered into License Agreement with Pharmosa Biopharm Inc. valued at Upfront payment of $10 million; potential development milestone payments up to $30 million; potentia (effective 2023-06-28).","evidence_excerpt":"License Agreement with Pharmosa Biopharm On June 28, 2023, Liquidia Technologies, Inc., a Delaware corporation (the “Liquidia Technologies”) and a wholly owned subsidiary of Liquidia Corporation","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1819576/000110465923075439/0001104659-23-075439-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"Pharmosa Biopharm Inc."},{"label":"Value","value":"Upfront payment of $10 million; potential development milestone payments up to $30 million; potentia"},{"label":"Effective","value":"2023-06-28"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}